TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1053427

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 129

Group type: COMPARATOR
Intervention: Close observation for early signs of meningitis
Number of subjects: 129
Study: 30633755

Group type: EXPERIMENTAL
Intervention: Epidural electric stimulation-guided epidural analgesia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Loss of resistance technique
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Epidural electric stimulation-guided epidural analgesia (only patients without motor blockade)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Loss of resistance technique (only patients without motor blockade)
Number of subjects: 62
Study: 28948663

Group type: EXPERIMENTAL
Intervention: ECHO (Experienced Caregivers Helping Others)
Number of subjects: 149

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: TAU plus ECHO with telephone guidance
Number of subjects: 149
Study: 25027640

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2. mA) over the left primary motor area (M1) for 20 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study: 24858755

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) followed by placement of Atridox gel (10% doxycycline hyclate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 12
Study: 21732954

Group type: EXPERIMENTAL
Intervention: Fibre-reinforced composite (FRC)/Duolink resin cement
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gutta-percha/AH Plus
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Plunger diameter 1.25 mm (FRC group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Plunger diameter 0.75 mm and 1 mm (FRC group)
Number of subjects: 90
Study: 19628729

Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa (100 mg/25 mg bid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rotigotine (initial dose 2 mg/24 h for 3 days, followed by 4 mg/24 h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combination of levodopa/carbidopa and rotigotine
Number of subjects: 24
Study: 16496410

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1805
Study: 15134155

Group type: EXPERIMENTAL
Intervention: FertilityBlend (nutritional supplement)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10518174

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Sertraline + Group Cognitive Behavior Therapy
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavior Therapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 7758060

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg BID
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg BID
Number of subjects: 930
Study: 2320558

Group type: EXPERIMENTAL
Intervention: High blood pressure feedback
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal blood pressure feedback
Number of subjects: 40
Study: 448576

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.25 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.3 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indomethacin (all doses)
Number of subjects: 9
Study: 31920295

Group type: EXPERIMENTAL
Intervention: BGF MDI 320/18/9.6μg
Number of subjects: 416
Study: 27881011

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy combined with bevacizumab intraperitoneal (i.p.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy combined with bevacizumab intravenous (i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy only
Number of subjects: 0
Study: 24729134

Group type: EXPERIMENTAL
Intervention: Experimental exposure to non-violent pornography
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Past pornography consumption
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lower levels of agreeableness
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sexual arousal (mediating effect)
Number of subjects: 200
Study: 24363218

Group type: EXPERIMENTAL
Intervention: Extended electromyostimulation (exEMS)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Limited electromyostimulation (limEMS)
Number of subjects: 31
Study: 22628120

Group type: EXPERIMENTAL
Intervention: Amoxycillin clavulanate (22.5 mg/kg/dose, twice daily for 2 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Amoxycillin clavulanate
Number of subjects: 50
Study: 19716960

Group type: EXPERIMENTAL
Intervention: Roflumilast (500 microg once per day)
Number of subjects: 3091

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3091
Study: 17887949

Group type: EXPERIMENTAL
Intervention: 200 mg/day silymarin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: COMPARATOR
Intervention: Glibenclamide alone
Number of subjects: 59
Study: 15202038

Group type: EXPERIMENTAL
Intervention: Risk factor specific assignment
Number of subjects: 309

Group type: COMPARATOR
Intervention: Conventional assignment
Number of subjects: 309
Study: 12231521

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (1 x 10(6) IU/m(2)/day s.c. for 90 days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 with intermediate pulse doses (6-12 x 10(6) IU/m(2)/day s.c. for 3 days every 14 days, maximum five pulses)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 with or without intermediate pulse dose therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 with intermediate pulse doses
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: NKG2D ligands expression in leukemic cells
Number of subjects: 35
Study: 9824783

Group type: EXPERIMENTAL
Intervention: Ganciclovir 1,000 mg six times a day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ganciclovir 1,500 mg four times a day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ganciclovir 2,000 mg three times a day
Number of subjects: 22
Study: 8084907

Group type: COMPARATOR
Intervention: Medium-fat/medium-carbohydrate (MFMC) lunch (45% fat, 42% carbohydrate, 12% protein)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-fat/high-carbohydrate (LFHC) lunch (29% fat, 54% carbohydrate, 15% protein)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-fat/low-carbohydrate (HFLC) lunch (62% fat, 24% carbohydrate, 13% protein)
Number of subjects: 18
Study: 2789919

Group type: EXPERIMENTAL
Intervention: Pergolide 25 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Timolol 20 mg (positive control)
Number of subjects: 12
Study: 31132996

Group type: EXPERIMENTAL
Intervention: Telephone-delivered psycho-behavioural intervention
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Psychological behavioural support (during maintenance phase)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Regular telephone contacts from counsellors (control group during intensive phase)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Regular telephone contacts from counsellors (control group during maintenance phase)
Number of subjects: 236
Study: 29223427

Group type: EXPERIMENTAL
Intervention: Inoue technique
Number of subjects: 302

Group type: COMPARATOR
Intervention: double-balloon technique
Number of subjects: 302
Study: 26350766

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 24704893

Group type: EXPERIMENTAL
Intervention: Health literacy tools (Ask Me 3™, Four Habits Model, Teach-back)
Number of subjects: 160
Study: 22860014

Group type: EXPERIMENTAL
Intervention: Dual blockade with enalapril (20 mg o.d.) and candesartan (16 mg o.d.)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Monotherapy with enalapril or candesartan
Number of subjects: 67
Study: 19010583

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) levels of IL-8
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) levels of IL-6
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale (GOS) score at 6 months after ROSC
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cutoff values for IL-8
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cutoff values for IL-6
Number of subjects: 13
Study: 18173005

Group type: EXPERIMENTAL
Intervention: Lactofem (viable Lactobacilli)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15121053

Group type: EXPERIMENTAL
Intervention: Antiparkinsonian medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wavelet analysis of EMG signals
Number of subjects: 0
Study: 11290882

Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9926909

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 8067592

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 167

Group type: COMPARATOR
Intervention: Astemizole
Number of subjects: 167
Study: 3177010

Group type: EXPERIMENTAL
Intervention: 5 mg bromocriptine
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 119
Study: 31833918

Group type: EXPERIMENTAL
Intervention: Children's concerns related to their mother's breast cancer diagnosis
Number of subjects: 140
Study: 30894306

Group type: EXPERIMENTAL
Intervention: Small Sided Game (SSG) training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Generic Fitness Training (GFT)
Number of subjects: 20
Study: 28753863

Group type: EXPERIMENTAL
Intervention: NSS
Number of subjects: 541

Group type: COMPARATOR
Intervention: RN
Number of subjects: 541
Study: 26001717

Group type: EXPERIMENTAL
Intervention: Individual psychoeducation program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 25931327

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT) alone
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Nutritional supplements alone
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Both CBT and nutrition
Number of subjects: 219

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 219
Study: 21453368

Group type: EXPERIMENTAL
Intervention: Large-tip catheter (LTC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open-irrigation-tip catheter (OITC)
Number of subjects: 60
Study: 17641378

Group type: EXPERIMENTAL
Intervention: RFA-PEI
Number of subjects: 133

Group type: COMPARATOR
Intervention: RFA alone
Number of subjects: 133
Study: 16227417

Group type: EXPERIMENTAL
Intervention: Spa resort treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (rehabilitation hospital)
Number of subjects: 120
Study: 12044434

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intermittent cross‐clamp fibrillation (ICCF)
Number of subjects: 30
Study: 10458255

Group type: EXPERIMENTAL
Intervention: Multilevel treatment algorithm based on the Agency for Health Care Policy and Research Guidelines for Cancer Pain Management
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard‐practice pain and symptom management therapies
Number of subjects: 81
Study: 7842187

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (mean 10.1 mg daily)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (15 mg daily for 7 days)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (500 micrograms twice daily for 7 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control subjects (not taking oral steroids)
Number of subjects: 34
Study: 2145871

Group type: EXPERIMENTAL
Intervention: UK 69,578 (10 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UK 69,578 (0.025 to 10.0 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UK 69,578
Number of subjects: 16
Study: 861153

Group type: EXPERIMENTAL
Intervention: isoetharine or isoprenaline
Number of subjects: 17

Group type: COMPARATOR
Intervention: sodium cromoglycate
Number of subjects: 17
Study: 28869786

Group type: EXPERIMENTAL
Intervention: 0.5 mg dose of lorazepam
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2 mg dose of lorazepam
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 0.3 mg dose of lorazepam
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1.2 mg dose of lorazepam
Number of subjects: 13
Study: 27278276

Group type: EXPERIMENTAL
Intervention: 6-week home-based exercise intervention consisting of 45 minutes of moderate-intensity (60-65% peak oxygen uptake) arm-crank exercise four times per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle maintenance (Control group)
Number of subjects: 0
Study: 24342775

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 22321963

Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan 300/320 mg
Number of subjects: 451

Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 451
Study: 21194249

Group type: EXPERIMENTAL
Intervention: Meriva® (curcumin-phosphatidylcholine complex)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 18528401

Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil citrate
Number of subjects: 601
Study: 15986954

Group type: EXPERIMENTAL
Intervention: PQ1 + SureFil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop + SureFil with flowable resin composite
Number of subjects: 60

Group type: COMPARATOR
Intervention: SureFil
Number of subjects: 60

Group type: COMPARATOR
Intervention: PermaFlo + SureFil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Air‐abrasive technique
Number of subjects: 60
Study: 12682621

Group type: EXPERIMENTAL
Intervention: High dose losartan (100 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amlodipine (10 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (normotensive rHuEPO dependent patients)
Number of subjects: 40
Study: 10726921

Group type: EXPERIMENTAL
Intervention: 150 mg vanadyl sulfate (VOSO4)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 300 mg vanadyl sulfate (VOSO4)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 150 mg and 300 mg vanadyl sulfate (VOSO4)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: vanadyl sulfate
Number of subjects: 16
Study: 8934373

Group type: EXPERIMENTAL
Intervention: Lacidipine (2-6 mg)
Number of subjects: 16590

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 16590
Study: 1527233

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg orally followed by adinazolam 30 mg 1 hour later (treatment A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Adinazolam alone (treatment B)
Number of subjects: 12
Study: 4014629

Group type: EXPERIMENTAL
Intervention: Intravenous meptazinol 2 mg/kg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 64
Study: 28467137

Group type: EXPERIMENTAL
Intervention: Expressive disclosure
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Benefit finding
Number of subjects: 64

Group type: COMPARATOR
Intervention: Time-management control
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: All writing conditions
Number of subjects: 64
Study: 26059860

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (LDV/SOF)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir + Ribavirin (LDV/SOF + RBV)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Successful viral clearance (N = 149)
Number of subjects: 154
Study: 24656949

Group type: EXPERIMENTAL
Intervention: Fresh Facts intervention (automated email messages promoting fruit and vegetable consumption every 3 days for 1 month)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study: 22158262

Group type: EXPERIMENTAL
Intervention: Real-time visual feedback using Nintendo Wii Balance Boards (NWBBs)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 47
Study: 20541069

Group type: EXPERIMENTAL
Intervention: Perioperative β-blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard practice as per ACC/AHA guidelines
Number of subjects: 0
Study: 17657327

Group type: EXPERIMENTAL
Intervention: Pharmacological intervention with telephone monitoring (TM)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Usual therapy (TH)
Number of subjects: 345
Study: 15757075

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no statin therapy)
Number of subjects: 0
Study: 22072154

Group type: EXPERIMENTAL
Intervention: Entecavir therapy (4 doses)
Number of subjects: 10
Study: 10687258

Group type: EXPERIMENTAL
Intervention: Candesartan cilexitil 16 mg
Number of subjects: 128

Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 128
Study: 8701872

Group type: EXPERIMENTAL
Intervention: Probucol (0.5 mg/day) administered between >7 days before PTCA and 3 months after PTCA
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no probucol)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Probucol (0.5 mg/day)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Probucol blood concentration
Number of subjects: 118
Study: 1341324

Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy and selective radiotherapy to the brain for stage pT1-3N0M0 patients.
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Surgery followed by chemotherapy for stage pT1-3N2M0 patients.
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Initial surgery for resectable tumors followed by postoperative chemotherapy.
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy followed by adjuvant surgery.
Number of subjects: 186
Study: 6391495

Group type: EXPERIMENTAL
Intervention: Injectable gold
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral gold
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31552831

Group type: EXPERIMENTAL
Intervention: Maternal pertussis vaccination within the first three postpartum days
Number of subjects: 405

Group type: COMPARATOR
Intervention: Unvaccinated mothers
Number of subjects: 405
Study: 30025255

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioral Therapy (GCBT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Fluoxetine (FLX) and GCBT
Number of subjects: 83
Study: 26223239

Group type: EXPERIMENTAL
Intervention: Moderate lifestyle intervention including individualized counseling on diet, physical activity, and weight control; one group meeting with a dietitian.
Number of subjects: 293

Group type: COMPARATOR
Intervention: Standard antenatal care (control group).
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Moderate lifestyle intervention.
Number of subjects: 293
Study: 23078583

Group type: EXPERIMENTAL
Intervention: B-BAES (6-item Brief Biphasic Alcohol Effects Scale)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: B-BAES
Number of subjects: 104
Study: 21440878

Group type: COMPARATOR
Intervention: Traditional Acupuncture (TA)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combined Acupuncture (CA)
Number of subjects: 49
Study: 19426180

Group type: EXPERIMENTAL
Intervention: Essential oils-containing mouthrinse
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16766781

Group type: EXPERIMENTAL
Intervention: Cereal (acidogenic) foods
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fruit and vegetable (alkalinogenic) foods
Number of subjects: 40
Study: 15532669

Group type: EXPERIMENTAL
Intervention: Word training (training to identify the number of moras in Japanese words spoken in isolation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentence training (training to identify the number of moras in Japanese words spoken in sentences)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentence training
Number of subjects: 0
Study: 11518201

Group type: EXPERIMENTAL
Intervention: Margarine enriched with 1.5 g/d plant sterols
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Margarine enriched with 3.0 g/d plant sterols
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control spread (rapeseed oil-based)
Number of subjects: 155
Study: 9289524

Group type: EXPERIMENTAL
Intervention: Systematic brief advice with support material and a five visit program during a year
Number of subjects: 139

Group type: COMPARATOR
Intervention: Once brief advice and a control in 1 year
Number of subjects: 139
Study: 7687364

Group type: EXPERIMENTAL
Intervention: DSG low dose
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: DSG high dose
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 3814446

Group type: EXPERIMENTAL
Intervention: Right ventricular pacing for 12 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no pacing)
Number of subjects: 16
Study: 29131699

Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) evaluated by polymerase chain reaction analysis of Ig/TCR gene rearrangements
Number of subjects: 3113

Group type: EXPERIMENTAL
Intervention: High-risk genetics and T-cell acute lymphoblastic leukemia
Number of subjects: 3113

Group type: EXPERIMENTAL
Intervention: Each log reduction in disease level
Number of subjects: 3113

Group type: EXPERIMENTAL
Intervention: Integration of genetic subtype-specific MRD values
Number of subjects: 3113
Study: 27615048

Group type: EXPERIMENTAL
Intervention: Stress Management Program (SMP)
Number of subjects: 40
Study: 24504100

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg IV every 3 months for 24 months)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 70